Proportion of trans urethral prostatectomy for benign hyperplasia on total prostatectomy

There are several treatment options for the treatment of benign prostatic hyperplasia: pharmacological treatment, aimed at improving quality of life by mitigating disuric symptomatology, watchful waiting for patients at low risk of pathology progression and surgical treatment, usually a transurethral prostatectomy (TURP). The choice of each of the therapeutic options requires an assessment of the risks and benefits and often this assessment is entrusted to the doctor, who will have to check if there are indications for surgery. The “Proportion of trans urethral prostatectomy for benign hyperplasia on total prostatectomy” measures the number of prostatectomies for which there would not seem to be a clear indication to the intervention on the total of all prostatectomies carried out in a structure. The indicator “Hospitalisation for trans-urethral prostatectomy for benign hyperplasia of the prostate” allows to measure the variability of hospitalisation rates between geographical areas and to identify a potential overuse or under use of surgical technique, since it is unlikely that the indications for TURP may vary systematically between the areas concerned. More information about: http://95.110.213.190/prevale2014/